
Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target
Supernus Pharmaceuticals (SUPN) Analyst Ratings
Bulls say
Supernus Pharmaceuticals Inc. is gaining attention for its innovative product, ONAPGO, aimed at treating advanced Parkinson's disease, which suggests a growing interest and potential market traction in its pipeline. The company has a history of conservative management, indicating that they might increase peak sales estimates as they understand demand dynamics better. The positive sentiment surrounding ONAPGO, coupled with the broader neuroscience portfolio that addresses critical neurological and psychiatric conditions, supports a favorable outlook for Supernus Pharmaceuticals.
Bears say
Supernus Pharmaceuticals Inc faces significant commercial execution risks, which could hinder its market potential and negatively impact revenue growth. Additionally, the inherent risks associated with clinical trials could lead to unfavorable outcomes, including the possible rejection of regulatory approvals due to insufficient evidence of drug efficacy and safety. These factors collectively contribute to a concerning outlook for the company's future financial performance and ability to expand its product portfolio.
This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Supernus Pharmaceuticals (SUPN) Analyst Forecast & Price Prediction
Start investing in Supernus Pharmaceuticals (SUPN)
Order type
Buy in
Order amount
Est. shares
0 shares